Spyre Therapeutics Inc expected to post a loss of 95 cents a share - Earnings Preview

Spyre Therapeutics

07/08/2024 16:31

* Spyre Therapeutics Inc  SYRE.OQ   SYRE.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 9
(estimated) for the period ending June 30 2024
    * The Waltham Massachusetts-based  company is expected to
report a
481.4% increase in revenue to $4 million from $688 thousand a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Spyre Therapeutics Inc
is for
a loss of 95 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $50.00​, above​ its last closing price
of $26.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.18       -1.17      -1.20     Missed  -2.9
 Jan. 1 0001   -0.52       -0.78      -4.05     Missed  -416.4
 Jan. 1 0001   -0.68       -0.84      -9.34     Missed  -1,005
                                                        .3​
 Jun. 30 2023  -4.50       -4.50      -41.50    Missed  -822.2
 ​​Jan.        -4.75       -4.50      -5.00     Missed  -11.1
 1 0001                                                 
 Jan. 1 0001   -5.04       -5.00      -4.50     Beat    10​
 Jan. 1 0001   -5.79       -5.80      -4.75     Beat    18.1
 Jun. 30 2022  -7.71       -7.79      -6.75     Beat    13.4
 This summary was machine generated August 7 at 15:31 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)